Pleural Disease Pathology — Effusion and Mesothelioma

PLEURAL EFFUSION MECHANISMS

Increased Hydrostatic Pressure

• Elevation of systemic venous pressure (right heart failure, constrictive pericarditis) or pulmonary venous pressure (mitral stenosis, left heart failure)
• Starling forces shift toward filtration; normal pleural fluid production (0.01 mL/kg/day) is overwhelmed
• Net result: transudative effusion with fluid-to-plasma protein ratio <0.5 and LDH ratio <0.6
• Pleural visceral surface remains intact; no inflammatory infiltration

Decreased Plasma Oncotic Pressure

• Severe hypoproteinemia (<2.5 g/dL) from nephrotic syndrome, cirrhosis, or malnutrition reduces oncotic gradient
• Fluid shifts from intravascular to interstitial and pleural spaces
• Results in low-protein transudates despite intact pleural membranes

Increased Vascular Permeability

• Inflammatory mediators (IL-1, IL-6, TNF-α, prostaglandins) and direct cellular injury breach endothelial tight junctions
• Occurs in infection (parapneumonic effusion), malignancy, pulmonary infarction, connective tissue disease
• Exudative effusion results: fluid-to-plasma protein >0.5, LDH ratio >0.6, elevated cellularity (predominantly lymphocytes or neutrophils depending on etiology)
• Histologically: fibrin deposition, inflammatory cell infiltration, capillary dilation

Impaired Lymphatic Drainage

• Obstruction of thoracic duct or mediastinal lymph nodes (malignancy, sarcoidosis, tuberculosis) prevents normal fluid resorption
• Accumulation occurs despite normal pleural permeability
• Produces exudative effusion with predominant lymphocytosis and often elevated LDH
• May produce chylothorax (triglyceride >110 mg/dL, milky appearance) if thoracic duct rupture or obstruction

Pleural Inflammation and Cellular Involvement

• Malignant cells invade visceral pleura → breach of mesothelial barrier
• Direct tumor secretion of permeability factors (vascular endothelial growth factor—VEGF)
• Hemorrhagic exudative effusion with malignant cells, elevated LDH (often >600 IU/L)
• Histology: fibrin-rimmed effusion with infiltrating malignant cells, reactive mesothelial proliferation

MESOTHELIOMA PATHOPHYSIOLOGY

Asbestos-Induced Carcinogenesis

• Crocidolite and amosite fibers (amphibole asbestos) are highly carcinogenic due to high aspect ratio (length-to-width >3:1) and biopersistence
• Fibers deposit in distal lung and migrate to visceral pleura through lymphatic channels
• Long latency period (20–50 years) reflects accumulation of multiple genetic hits
• Fibers trigger chronic inflammatory cascade: resident macrophages, neutrophils, and lymphocytes produce reactive oxygen species (ROS), TNF-α, IL-1β, IL-6

Molecular and Cellular Alterations

• Loss of tumor suppressors: p53 mutations (~50%), CDKN2A/p16 homozygous deletion (~70% in epithelioid type), BRCA1 alterations
• Activation of oncogenic pathways: NF-κB hyperactivation (persistent inflammatory signaling), Wnt/β-catenin, hedgehog signaling
• Direct genotoxic injury from asbestos: DNA double-strand breaks, chromosomal instability
• Escape from apoptosis: elevated anti-apoptotic proteins (Bcl-2 family), loss of p53-mediated apoptosis
• Epithelial-to-mesenchymal transition (EMT): loss of E-cadherin, upregulation of mesenchymal markers (vimentin, N-cadherin)
• Enhanced invasiveness and metastatic potential via matrix metalloproteinase secretion

Progressive Pleural Invasion

• Neoplastic mesothelial cells proliferate from visceral pleura initially, often remaining localized for extended period
• Infiltration of pleural connective tissue and parietal pleura
• Encasement of lung, mediastinal structures, and diaphragm
• Pleural thickening (often >5 mm) with nodular or denuding pattern on imaging and gross examination
• Effusion develops from tumor angiogenesis, inflammation, and lymphatic obstruction

PLEURAL EFFUSION ETIOLOGIES

Transudative Causes (>70% of hospital-acquired effusions)

• Congestive heart failure (most common cause—60% of transudates)
• Cirrhosis with portal hypertension
• Nephrotic syndrome
• Hypoproteinemia from any cause (malnutrition, protein-losing enteropathy)
• Peritoneal dialysis (transdiaphragmatic transfer)

Exudative Causes (Non-malignant)

• Parapneumonic effusions/empyema (bacterial pneumonia, complicated by fibrin loculation and bacteria in fluid—requires drainage)
• Tuberculosis (most common infectious cause globally; lymphocytic predominance, often chronic, can calcify)
• Viral infections (influenza, COVID-19), fungal infection (histoplasmosis, coccidioidomycosis)
• Pulmonary embolism (hemorrhagic, exudative; elevated LDH from infarction)
• Autoimmune/connective tissue disease: systemic lupus erythematosus (low complement, antinuclear antibodies), rheumatoid arthritis (low glucose <30 mg/dL, cholesterol crystals), Sjögren syndrome
• Pancreatitis (amylase >upper limit of serum)
• Esophageal rupture (Boerhaave syndrome—high amylase, mediastinitis)
• Drug reactions (nitrofurantoin, methotrexate, statins)
• Post-cardiac surgery (dressler-like syndrome)
• Asbestos exposure (benign asbestos pleural effusion—inflammatory response without malignancy)

Malignant Effusions

• Metastatic carcinoma (lung, breast, ovarian, gastric, lymphoma)
• Mesothelioma (primary pleural malignancy)
• Direct chest wall or mediastinal tumor invasion

MESOTHELIOMA RISK FACTORS

Occupational/Environmental Asbestos Exposure

• Mining, milling, manufacturing of asbestos products
• Construction, insulation installation, brake repair
• Shipyard workers, military veterans (ship insulation)
• Secondary exposure: household exposure from contaminated clothing of workers
• Latency period typically 20–50 years (range 10–70 years); dose and fiber type correlate with risk

Predisposing Genetic Factors

• Simian virus 40 (SV40) co-infection: controversial association; found in some mesotheliomas; may act as co-carcinogen
• Familial clustering reported but rare; no established Mendelian inheritance pattern
• Possible germline BAP1 mutations (BRCA1-associated protein 1) increase susceptibility

Non-Occupational Risk

• Talc exposure (occupational talcum powder use, contaminated with asbestos)
• Previous chemotherapy (peritoneal mesothelioma risk)
• Thorotrast (discontinued contrast agent containing thorium dioxide)
• Radiation therapy to chest

PLEURAL EFFUSION

Cardinal Symptoms

• Dyspnea (most common; due to mechanical splinting of lung expansion, ventilation-perfusion mismatch, reduced chest wall compliance)
• Pleuritic chest pain (sharp, worse with deep inspiration or cough; indicates pleural inflammation—absent in simple transudates)
• Dry cough (irritation of visceral pleura)
• Orthopnea and paroxysmal nocturnal dyspnea if massive

Physical Examination Findings

• Decreased breath sounds over affected area (fluid dampens vibrations)
• Dullness to percussion (classic finding of fluid accumulation >250 mL)
• Absent tactile fremitus (fluid blocks vibration transmission)
• Reduced expansion on affected side
• Tracheal deviation toward affected side if massive compression (displacement sign)
• Asymmetry of expansion

Morphological Correlates

• Small effusions (<300 mL) may be asymptomatic, detected only on imaging
• Layering of fluid on lateral decubitus chest X-ray confirms effusion (not subpulmonary fluid or thickened pleura)
• Bilateral effusions suggest systemic disease (heart failure, malignancy, lupus)
• Rapidly accumulating effusions cause acute dyspnea; chronic effusions allow compensatory adaptation

MESOTHELIOMA

Early Presentation (often delayed diagnosis—years after exposure)

• Insidious onset of chest pain (often pleuritic, unilateral; infiltration of parietal pleura with nociceptors)
• Persistent dyspnea from growing effusion and pleural thickening
• Cough (dry or productive depending on lung involvement)
• Constitutional symptoms (low-grade fever, night sweats, weight loss) in advanced disease
• Often asymptomatic initially; discovered incidentally on imaging for other reasons

Physical Examination

• Unilateral pleural effusion (asymmetric)
• Reduced breath sounds and dullness over affected hemithorax
• Chest wall rigidity or restricted expansion (pleural encasement)
• Palpable nodularity or thickening along chest wall (direct pleural invasion)
• Horner syndrome if apical tumor involves superior cervical sympathetic chain
• Facial/upper extremity edema (superior vena cava obstruction from mediastinal involvement)

Imaging and Laboratory Findings

• Chest X-ray: unilateral pleural effusion with ipsilateral pleural thickening (hallmark finding)
• CT imaging: irregular, nodular pleural thickening (>3 mm), pleural calcification (unusual), infiltration of mediastinal fat, encasement of lung
• Restricted hemithorax sign: mediastinal shift away from tumor despite large effusion (indicates fixed pleural disease, not simple fluid)
• MRI: superior for assessing chest wall and diaphragmatic invasion
• PET-CT: hypermetabolic pleural disease (SUV often elevated)

PLEURAL EFFUSION

Clinical Suspicion and Imaging

• Chest X-ray (posterior-anterior and lateral) or CT shows fluid in pleural space
• Blunting of costophrenic angle (>250 mL accumulation) is earliest finding
• Meniscus sign on lateral view (concave meniscus)
• Lateral decubitus view: fluid layers along chest wall if free-flowing (>250 mL required)
• Ultrasound: highly sensitive for small effusions; allows real-time assessment of fluid characteristics (simple, echogenic, complex) and guides safe thoracentesis

Thoracentesis and Pleural Fluid Analysis

• Clear, straw-colored = simple transudative effusion
• Turbid, milky = chylothorax or complicated parapneumonic
• Hemorrhagic = malignancy, pulmonary embolism, trauma
• Purulent = empyema (septic; requires immediate drainage)

• Pleural fluid-to-serum protein ratio >0.5, OR
• Pleural fluid-to-serum LDH ratio >0.6, OR
• Pleural LDH >⅔ upper limit of normal serum value
• If any criterion met = exudate (88% sensitive, 86% specific for detecting exudative processes)

• Transudates: <1,000 cells/μL (mostly mesothelial cells and macrophages; <50% neutrophils)
• Parapneumonic: neutrophil-predominant (>50%), counts often 1,000–50,000 cells/μL
• Malignancy: variable but often lymphocyte-predominant initially; RBC present if hemorrhagic; malignant cells may be sparse
• Tuberculosis: lymphocyte-predominant (>60%), monocytes also present, low glucose (<45 mg/dL), elevated ADA (adenosine deaminase >10 U/L), LDH markedly elevated
• Rheumatoid arthritis: low glucose (<30 mg/dL), cholesterol crystals visible, immune complexes present
• Lupus: reduced complement, LE cells (pathognomonic but rarely performed)
• Chylothorax: opalescent/milky, lymphocyte-predominant; confirmed by triglyceride >110 mg/dL and lipoprotein electrophoresis showing chylomicrons

• Glucose: low (<30) in rheumatoid, tuberculosis, empyema; normal in most others
• LDH: markedly elevated in malignancy, tuberculosis, pulmonary embolism
• pH: low (<7.20) in empyema and some complicated parapneumonic (indicates acidosis, need for drainage)
• Amylase: elevated in pancreatitis, esophageal rupture, malignancy
• Cholesterol/triglyceride: cholesterol crystals in rheumatoid; triglycerides in chylothorax

• Gram stain and culture (bacteria, mycobacteria)
• AFB smear for tuberculosis
• Fungal culture if immunocompromised
• PCR for tuberculosis (higher sensitivity than smear)

• Sensitivity ~60–70% for malignant effusions (poor single test; requires multiple thoracenteses for higher yield)
• Specific for confirming malignancy: malignant cells show increased nucleus-to-cytoplasm ratio, irregular nuclear membranes, coarse chromatin, prominent nucleoli
• Adenocarcinoma (most common malignant effusion): glandular arrangement, mucinous material
• Small cell carcinoma: scant cytoplasm, molding
• Lymphoma: atypical lymphocytes, monoclonal population (flow cytometry)

Pleural Biopsy (Closed or Image-Guided)

• Indicated if malignancy suspected but cytology negative
• Sensitivity ~80% for malignancy (superior to fluid cytology alone)
• Histology shows infiltrating malignant cells within pleural tissue
• Useful for diagnosing granulomatous disease (tuberculosis, sarcoidosis) and distinguishing mesothelioma from adenocarcinoma

Imaging Assessment

• Pleural thickening >3 mm suggests malignancy or tuberculosis (simple transudates don't thicken pleura)
• Pleural calcification: asbestos-related disease, tuberculosis (rare in mesothelioma)

MESOTHELIOMA

Gross Pathology

• Nodular, thickened pleura (often >5 mm; may encircle entire lung)
• Tan to gray-white appearance with areas of hemorrhage, necrosis (especially in biphasic/sarcomatoid types)
• Rindlike encasement of lung parenchyma with restriction of expansion
• Visceral and parietal ple

Immediate stabilisation

• Therapeutic thoracentesis: for a large effusion causing hypoxaemia or respiratory distress, ultrasound-guided drainage is the first act. Limit a single-session removal (large-volume drainage risks re-expansion pulmonary oedema); stop for chest tightness or cough.
• Tube thoracostomy: frank pus, positive Gram stain/culture, loculation, or pleural fluid pH <7.20 defines a complicated parapneumonic effusion/empyema and mandates drainage in addition to antibiotics (IDSA/ATS community-acquired pneumonia guidance).

First-line therapy — treat the driver

• Loop diuretics (e.g., furosemide) plus guideline-directed HFrEF therapy — ARNI or ACEI/ARB, beta blocker, MRA, and SGLT2 inhibitor — per the ACC/AHA/HFSA heart failure guideline; most transudates resolve without any pleural procedure.
• Antibiotics with anaerobic coverage (e.g., ampicillin-sulbactam) for parapneumonic effusion; RIPE therapy for tuberculous pleuritis per ATS/CDC/IDSA; sodium restriction, diuretics and transplant evaluation for hepatic hydrothorax (AASLD).

Escalation

• Intrapleural fibrinolytic plus DNase (alteplase + dornase alfa) for loculated empyema failing tube drainage.
• Symptomatic recurrent malignant effusion: the ATS/STS/STR guideline supports either talc pleurodesis or an indwelling pleural catheter; an indwelling catheter is preferred when the lung is nonexpandable (trapped lung), in which pleurodesis will fail.
• Mesothelioma: per NCCN, systemic therapy with platinum + antifolate (cisplatin plus pemetrexed, with folate/B12 supplementation) or dual checkpoint blockade (nivolumab plus ipilimumab), favoured particularly in non-epithelioid histology.

Definitive/surgical

• VATS decortication for organised empyema or fibrothorax.
• Pleurectomy/decortication or extrapleural pneumonectomy in highly selected early-stage epithelioid mesothelioma, at experienced centres, within multimodality protocols.

Contraindicated/avoid

• Pleurodesis in trapped lung; drainage through infected chest wall skin; delaying drainage of empyema while awaiting culture; relying on antibiotics alone for purulent fluid; and thoracentesis without imaging guidance where feasible.

Procedure-related (thoracentesis/chest tube)

• Iatrogenic pneumothorax: needle laceration of visceral pleura; signalled by new hypoxaemia, absent breath sounds, and post-procedure imaging. Tension pneumothorax — hypotension with tracheal deviation away from the lesion — is an emergency requiring immediate needle decompression.
• Haemothorax: laceration of the intercostal artery, which runs in the inferior costal groove; hence needle insertion over the superior border of the rib. Rapidly falling haematocrit with bloody output is the tell.
• Re-expansion pulmonary oedema: rapid removal of a large chronic effusion causes a surge in transpulmonary pressure and capillary leak in the collapsed lung; ipsilateral infiltrates with cough and hypoxaemia within hours. Potentially fatal — an emergency.
• Empyema/catheter tract infection from indwelling pleural catheters; talc-induced pneumonitis/ARDS after pleurodesis.

Disease-related

• Empyema and fibrothorax: fibrin deposition and organisation produce a restrictive rind and trapped lung; falling FVC with persistent pleural thickening.
• Bronchopleural fistula: persistent air leak with continuous bubbling in the drainage chamber; risks contralateral soiling — urgent.
• Sepsis from undrained empyema — emergency.
• Mesothelioma local invasion: chest wall pain from parietal pleural/rib involvement, Horner syndrome, superior vena cava syndrome (facial and upper-limb oedema, distended neck veins), and pericardial invasion causing tamponade with pulsus paradoxus and equalised diastolic pressures — both emergencies.
• Tumour seeding of instrument tracts after biopsy or catheter placement, appearing as subcutaneous nodules.

Treatment-related systemic toxicity

• Cisplatin: nephrotoxicity, ototoxicity, peripheral neuropathy; pemetrexed: myelosuppression and mucositis, mitigated by folate/B12 supplementation.
• Checkpoint inhibitors: immune-related colitis, hypophysitis, thyroiditis, and pneumonitis — new dyspnoea on nivolumab/ipilimumab should not be attributed to progression until pneumonitis is excluded; treated with corticosteroids per ASCO immune-related adverse event guidance.

• Ferruginous bodies: golden-brown, beaded asbestos fibres coated in iron and protein, highlighted by Prussian blue. They prove exposure, not malignancy — the classic distractor is calling them diagnostic of mesothelioma.
• Asbestos causes more bronchogenic carcinoma than mesothelioma. Smoking multiplies the lung-cancer risk synergistically but does not increase mesothelioma risk. Examiners test exactly this dissociation.
• Pleural plaques: well-circumscribed, calcified fibrous thickening of the parietal pleura and diaphragmatic dome. They are the commonest asbestos-related finding, are benign, and are not premalignant.
• Best next step for any new undiagnosed effusion: diagnostic thoracentesis (ultrasound-guided) and apply Light's criteria. In a patient already diuresed for heart failure, Light's criteria misclassify transudates as exudates — use the serum-to-pleural fluid albumin gradient (>1.2 g/dL favours a transudate).
• Pleural fluid pH <7.20 or frank pus = chest tube, not repeat thoracentesis. This single number is the commonest management item tested.
• Immunohistochemistry separates mesothelioma from metastatic adenocarcinoma: mesothelioma is calretinin, WT-1, CK5/6, and D2-40 positive; adenocarcinoma is CEA, MOC-31, claudin-4, and (if lung primary) TTF-1 positive. BAP1 loss and CDKN2A/p16 deletion support malignancy over reactive mesothelial hyperplasia.
• Epithelioid histology has the best prognosis; sarcomatoid the worst; biphasic is intermediate. Cytology alone is unreliable — pleural biopsy (thoracoscopic preferred) is required for diagnosis.
• Effusion character shortcuts: milky with triglycerides high = chylothorax; amylase high = pancreatitis or oesophageal rupture; glucose profoundly low with cholesterol crystals = rheumatoid pleuritis; lymphocyte-rich with high ADA = tuberculosis.
• Distractor to avoid: unilateral heart-failure effusions are typically right-sided, so a right transudate does not exclude cardiac origin — and never presume malignancy from bloody fluid alone (pulmonary embolism and trauma do the same).